School of Pharmacy, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand.
Health Policy. 2010 Jul;96(2):108-17. doi: 10.1016/j.healthpol.2010.01.012. Epub 2010 Feb 18.
Changes in the traditional model of drug development are creating a potential opportunity for New Zealand's drug development industry. This research evaluates whether New Zealand could utilise some of the policies employed by countries with successful drug development industries.
A framework to support a drug development industry was developed by taking into account policies that affect the industry. The framework was then used to analyse the types of policies provided by different countries and to postulate six different models that support a pharmaceutical industry.
Countries with a successful drug development industry have identified their strengths, analysed the opportunities in the industry, and have employed consistent and specific policies in support of their industry. New Zealand's policy in support of its drug development industry is most similar to that of the medical research-based model of the UK, Australia and Canada.
New Zealand needs to develop a consistent policy for support of its drug development industry based on identifying and focussing on the competencies where it is internationally competitive. A strong partnership with Australia could capitalise on the strengths of both countries and linkages with other Asia-Pacific countries could further promote the region's capabilities in drug development research.
药物开发传统模式的改变为新西兰的药物开发产业创造了潜在的机会。本研究评估了新西兰是否可以利用一些具有成功药物开发产业的国家所采用的政策。
通过考虑影响产业的政策，制定了一个支持药物开发产业的框架。然后，利用该框架分析了不同国家提供的政策类型，并提出了支持制药业的六种不同模式。
具有成功药物开发产业的国家已经确定了自己的优势，分析了产业中的机会，并采用了一致和具体的政策来支持其产业。新西兰支持其药物开发产业的政策与英国、澳大利亚和加拿大的以医学研究为基础的模式最为相似。
新西兰需要根据其具有国际竞争力的优势，制定一致的药物开发产业支持政策。与澳大利亚建立强有力的伙伴关系，可以利用两国的优势，与其他亚太国家建立联系，进一步促进该地区在药物开发研究方面的能力。
